- Pharmaceuticals: Interactive cost-utility Markov-Microsimulation model (MCMC) with Excel®, pathology: Venous leg ulcer. Interactive budget impact model with Excel®
- Pharmaceuticals: Interactive cost-utility Markov model with Excel®, pathology: Severe aortic stenosis (SAS).
- Pharmaceuticals: Bayesian multi-treatment meta-analysis with Winbugs/R, pathology: Severe aortic stenosis (SAS).
Maunoury F, Drugeon B, Boisson M, Marjanovic N, Couvreur R, Mimoz O, et al. Cost-effectiveness analysis of bundled innovative devices versus standard approach in the prevention of unscheduled peripheral venous catheters removal due to complications in France. PLoS ONE. 2022;17(6):e0269750.
May 2023. Early meetings with HAS-DEAI: Haute Autorité de Santé (HAS, DEAI), Paris.
"Presentation of cost-effectiveness and budget impact models in patients with myocardial infarction".
PRS55 - COST-EFFECTIVENESS OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA PATIENTS IN FRANCE.
F. Maunoury1, C. Pribil2, M. Aubier3, G. Nachbaur2, S. Doyle4
1 STATESIA, Le Mans, France; 2 GlaxoSmithKline, RueilMalmaison, France; 3 Bichat University Hospital, Paris, France; 4 GlaxoSmithKline, London, UK
